Concepedia

Jessica Thomes Pepin

JT

Statistics

Publications

6

Citations

411

H-Index

6

Active since

2019

Affiliations

Minnesota Oncology(Current)

National Cancer Institute

Indiana University Bloomington

Kurume University

Northwestern University

Jessica Thomes Pepin is an author at Minnesota Oncology specializing in oncology, gynecologic cancer pharmacotherapy, and endometrial cancer.

Publications per year

2019–2025

6

Publications

6

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Journal of Clinical Oncology · 2023 · 331 citations · Full text

, , +12

Interferon-γ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer

Horacio Cárdenas, Guanglong Jiang, Jessica Thomes Pepin et al. · npj Precision Oncology · 2019 · 30 citations · Full text

, , +17

Dostarlimab and niraparib in primary advanced ovarian cancer

Anne‐Claire Hardy‐Bessard, E. Pujade-Lauraine, Richard G. Moore et al. · Annals of Oncology · 2025 · 16 citations · Full text

, , +10

LBA41 Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Annals of Oncology · 2023 · 12 citations · Full text

, , +9

SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer

Young Kwang Chae, Megan Othus, Sandip Pravin Patel et al. · Clinical Cancer Research · 2024 · 11 citations · Full text

, , +17

1–5 of 6